Also available as PDF (figures and tables appear in the PDF).
Background: Type 2 diabetes mellitus (T2DM) in children and adolescents represents a rapidly escalating global public-health crisis. Evidence drawn from multiple continents indicates that the disease follows an accelerated, more aggressive course in youth than in adults, with multi-organ complications appearing far earlier than historically anticipated. Objectives: [1] To characterize the prevalence and cumulative incidence of each major complication domain in youth-onset T2DM using data from international cohorts; [2] to compare complication burden across geographic regions and ethnic populations; and [3] to identify modifiable risk factors to guide evidence-based clinical management. Methods: PubMed/MEDLINE, EMBASE, and the Cochrane Library were searched systematically from January 1995 to December 2023. Eligible studies enrolled participants aged ≤18 years with T2DM and reported at least one complication outcome. Thirty-eight studies (N = 42,610 participants across North America, Europe, Asia-Pacific, the Middle East, and Australia) met inclusion criteria. Quality was assessed using the Newcastle-Ottawa Scale (NOS) and the Cochrane RoB-2 tool; pooled estimates were generated using random-effects meta-analysis. Results: Across all regions, hypertension was the most frequent complication (pooled prevalence 42–68%), followed by diabetic kidney disease (DKD; 22–55%), dyslipidemia (38–52%), retinopathy (13–51%), and peripheral neuropathy (12–32%). MASLD/NAFLD affects 40–70% of patients globally. Data from the USA (TODAY, SEARCH), Asia-Pacific (JADE program), Europe (UK and Italian cohorts), multi-national meta-analyses (Nanayakkara et al., 26 countries), and Australia were convergent in demonstrating that each additional year of younger age at diagnosis conferred a 4–5% incremental increase in vascular complication risk. Mental health disorders affected 15–32% of youth with T2DM across all populations studied. Youth-onset T2DM consistently showed higher complication rates than both adult-onset T2DM of equivalent duration and youth-onset T1DM. Conclusions: Youth-onset T2DM imposes an internationally consistent, uniquely aggressive complication phenotype that transcends ethnic and geographic boundaries. Complications worldwide must implement complication screening from the time of diagnosis, integrate psychosocial support, and adopt newer pharmacotherapies with organ-protective properties. Investment in equitable, globally applicable, pediatric-specific protocols is urgently needed
Keywords: Type 2 diabetes mellitus; children; adolescents; complications; Cardiovascular; Neurological; Type2diabetesmellitus; Cardiovascular,Neurological
1.Introduction corroborated by a body of international evidence spanning at least four continents and 26 countries. Overthepastthreedecades,type2diabetesmellitus The landmark meta-analysis by Nanayakkara et al. (T2DM)inchildrenandadolescentshasevolvedfroma (Diabetologia,2021),synthesizingdatafrom1,325,493 clinicalcuriosityintoaglobalpandemicthatthreatens individuals, demonstrated that each one-year to overwhelm health systems on every continent. younger age at T2DM diagnosis was independently Driven principally by the worldwide epidemic of associated with 4% higher all-cause mortality, childhoodobesity,physicalinactivity,andunhealthy 3% higher macrovascular risk, and 5% higher dietarypatterns,incidentratesofpediatricT2DMare microvascularcomplicationriskafteradjustmentfor risingatalarmingpace[1].TheSEARCHforDiabetes currentage—aninversedose-responserelationship in Youth study in the United States documented a of compelling consistency across geographically 4.8%annualincreaseinyouth-onsetT2DMincidence and ethnically diverse populations [8]. Beyond between2002and2018[2]. Concurrently,theJADE classical microvascular and macrovascular disease, Programme, enrolling more than 41,000 patients youth-onset T2DM is increasingly recognized as from nine Asian countries, reported that one in a complex metabolic syndrome encompassing five adults attending diabetes clinics across Asia metabolic dysfunction-associated steatotic liver had been diagnosed before the age of 40 years, disease(MASLD,formerlyNAFLD),obstructivesleep signalling an impending generational epidemic [3]. apnea (OSA), and a substantial neuropsychiatric IntheUnitedKingdom,adecade-longanalysisofan burden including depression, anxiety, and eating inner-city London cohort documented a trebling in disorders (6,9,10). The JADE Program across Asia pediatric T2DM incidence between 2010 and 2020 demonstrated that, compared with late-onset [4]. These convergent international signals leave T2DMpatients, thosewithyoung-onsetdiseasehad no room for epidemiological complacency. The significantly worse glycemic control, lower use of pathobiologicalmechanismsunderlyingyouth-onset organ-protective medications, higher body mass T2DM differ meaningfully from adult-onset disease. index,andpoorerbloodpressureandlipidprofiles— The Restoring Insulin Secretion (RISE) Consortium collectively portending an even larger complication demonstrated, using both hyperglycemic clamps burden in future years [3]. In India, Australia, the and oral glucose tolerance tests, that adolescents Middle East, and Europe, analogous patterns of experience a markedly faster rate of beta-cell accelerated complication onset in young patients functionaldeclinethanadultsexposedtoequivalent have been reported, suggesting that the biological degreesofinsulinresistance[5].Thisrapidmetabolic aggressiveness of youth-onset T2DM is intrinsic to deterioration — exacerbated by pubertal insulin the disease process rather than a product of any resistance mediated by growth hormone and IGF-1 singlehealthcareenvironment(8,11,12).Acriticaland — shortens the interval between diagnosis and underappreciateddimensionofthisglobalproblem complication onset dramatically. Lascar et al., is the disproportionate burden borne by socially reviewingtheglobalevidenceinalandmarkLancet and economically marginalized populations. In the Diabetes & Endocrinology paper (2018), concluded United States, non-Hispanic Black and Hispanic that young-onset T2DM constitutes a distinctly youth carry complication rates two to three times aggressive disease phenotype carrying heightened higherthannon-HispanicWhitepeers(2,7).InSouth risksforprematurechroniccomplicationsandreduced Asia, where young-onset T2DM occurs at lower BMI life expectancy [6]. Young people diagnosed at thresholds and with a distinct pathophysiology age 15–40 years lose 8–15 years of life expectancy dominatedbycentraladiposityandinsulinsecretory compared with the general population, primarily deficiency,complicationratesareamongthehighest due to cardiovascular events [6]. Perhaps the most globally [12]. Indigenous populations in Australia, definitive single-study evidence on complication Canada,andNewZealandareaffectedwithparticular burden comes from the Treatment Options for severity, reflecting the convergence of genetic risk, Type 2 Diabetes in Adolescents and Youth (TODAY) socioeconomic disadvantage, and limited access study — a landmark US multicenter randomized to specialist care [13]. These inequalities demand trial that followed 500 participants for a mean of not merely clinical solutions but structural and 13.3 years to a mean age of 26.4 years [7]. By that policy-level interventions that address the social age, 67.5% had hypertension, 54.8% had diabetic determinantsofdiabeticcomplications. Despitethe kidneydisease, 51.6%haddyslipidemia, 51.0%had convergence of international evidence, the clinical retinopathy, and 32.4% had peripheral neuropathy communityhasbeenslowtotranslatethesefindings [7]. These extraordinary figures have now been intoappropriatelyaggressivesurveillanceprotocols Trials from January 1995 through December andtreatmentstrategies.TheInternationalSocietyfor 2023. Search terms were constructed from MeSH PediatricandAdolescentDiabetes(ISPAD)updatedits headings and free-text terms combining: ’type 2 ClinicalPracticeConsensus Guidelinesinboth2022 diabetes mellitus,’ ’children,’ ’adolescents,’ ’youth,’ and 2024, mandating complication screening from ’pediatric,’ ’young-onset,’ with each complication the time of T2DM diagnosis — a marked departure domain: ’diabetic nephropathy,’ ’diabetic kidney fromadultguidelinesthatdeferinitialscreeningfor disease,’ ’hypertension,’ ’dyslipidemia,’ ’NAFLD,’ several years (14,15). The 2024 guidelines further ’MASLD,’ ’retinopathy,’ ’neuropathy,’ ’cardiovascular endorsedliraglutideanddapagliflozinforyouthwith disease,’ ’atherosclerosis,’ ’obstructive sleep apnea,’ T2DM on the basis of emerging pediatric trial data, ’depression,’ ’anxiety,’ and ’mental health.’ Named recognizing that standard metformin monotherapy landmarkstudieswerealsosearcheddirectly(TODAY, is insufficient for the majority of patients [15]. The SEARCH, JADE, RISE, NDSS Australia). Reference presentsystematicreviewwasdesignedtoconsolidate lists of all included articles and relevant clinical and critically appraise the totality of international guidelines were hand-searched. No geographic, evidence on complications in youth-onset T2DM, ethnic, or language restriction was applied beyond drawingonstudiesfromNorthAmerica,Asia-Pacific, English-languagepublications.
Europe, Australia, the Middle East, and global meta-analyses,withtheexplicitgoalofproducinga 3.2 InclusionandExclusionCriteria balanced,globallyapplicableevidencebasetoguide Studieswereincludedifthey:(a)enrolledparticipants clinicalpracticeandfutureresearchinvestment. aged ≤18 years at diagnosis of T2DM, or reported subgroup results separately for this age category; 2.OBJECTIVES (b)reportedatleastonepre-specifiedcomplication outcome using clearly defined diagnostic criteria This systematic review addressed three primary consistent with ADA or WHO standards; (c) had objectives: [1] to characterize the prevalence, a minimum sample size of 30 participants; (d) cumulative incidence, and clinical features of were published in English between January 1995 each major complication domain — including and December 2023; and (e) were prospective or diabetickidneydisease,hypertension,dyslipidemia, retrospectivecohortstudies,randomizedcontrolled MASLD/NAFLD, cardiovascular disease, obstructive trials(RCTs),cross-sectionalstudieswith ≥12months sleepapnea,retinopathy,peripheralneuropathy,and follow-up, case-control studies with ≥ 50 cases, or mentalhealthdisorders—inchildrenandadolescents systematic reviews and meta-analyses covering the with T2DM, drawing on data from international relevantpediatricpopulation.Studieswereexcluded cohorts across multiple geographic regions; [2] to ifthey: enrolledexclusivelyadultpopulations(≥ 19 compare complication rates between youth-onset years)withoutapediatricsubgroupanalysis;lacked and adult-onset T2DM and between youth-onset clearly defined T2DM diagnostic criteria; focused T2DM and youth-onset T1DM, using geographically exclusively on T1DM; were conference abstracts, diversedatasetstodeterminetheconsistencyofthe editorials,casereports,oranimalstudies;orcontained higher-riskphenotypeacrosspopulations;and[3]to non-extractablecomplicationdata.
identifytheprincipalmodifiableandnon-modifiable risk factors for complication development across different ethnic and geographic settings, with the 3.3 DataExtractionandQualityAssessment aimofinformingevidence-based,globallyapplicable Datawereextractedindependentlybytworeviewers clinical guidelines for monitoring and treatment of using a standardized electronic form capturing: youth-onsetT2DM.
countryandhealthcaresystemcontext,studydesign, participant demographics (age, sex, race/ethnicity, BMI,diseaseduration),complicationdefinitionsand 3.METHODS ascertainment methods, prevalence or cumulative 3.1 StudyDesignandSearchStrategy incidencedata,andreportedriskfactorassociations. Thissystematicreviewwasconductedandreported Disagreements were resolved by consensus with a in accordance with the Preferred Reporting Items thirdreviewer. Qualityofobservationalstudieswas forSystematicReviewsandMeta-Analyses(PRISMA) assessedusingtheNewcastle-OttawaScale(NOS;0–9 2020 statement [16]. A comprehensive search stars; ≥6=goodquality). RCTqualitywasevaluated was performed in PubMed/MEDLINE, EMBASE, usingtheCochraneRiskofBiastoolversion2(RoB-2). and the Cochrane Central Register of Controlled Systematicreviewsandmeta-analyseswereappraised usingtheAMSTAR-2checklist.
longest longitudinal cohort specifically dedicated to pediatric T2DM, it is one of 14 landmark studies 3.4 StatisticalAnalysis included. TheJADEProgramcontributesthelargest Where two or more studies provided comparable Asian dataset (>41,000 participants from nine data for the same complication endpoint, countries);theNanayakkarameta-analysisprovides pooled prevalence estimates were calculated thebroadestglobalsynthesis(1.3millionparticipants, using random-effects meta-analysis with the 26countries);andEuropean,HongKong,Chinese,and DerSimonian-Laird method to account for Britishcohortsindependentlyconfirmtheaccelerated between-study heterogeneity. Heterogeneity was complicationphenotypeobservedinNorthAmerica. quantifiedusingtheI2statistic(thresholds:<25%low, Abbreviations: CV = coefficient of variation; DKD 25–75%moderate,>75%high).Pre-specifiedsubgroup = diabetic kidney disease; CVD = cardiovascular analyseswereperformedbygeographicregion(North disease; MASLD=metabolicdysfunction-associated America,Asia-Pacific,Europe,Australia/NewZealand, steatotic liver disease; OSA = obstructive sleep MiddleEast/SouthAsia),ethnicity,agegroup(10–13 apnea; HTN = hypertension; TG = triglycerides; vs14–18years),BMIcategory,anddiabetesduration HDL-C = high-density lipoprotein cholesterol; SBP (≤5vs>5years).Sensitivityanalyseswereperformed = systolic blood pressure; DBP = diastolic blood excluding studies at high risk of bias. Publication pressure; PHQ = Patient Health Questionnaire; DDS bias was evaluated visually with funnel plots and = Diabetes Distress Scale; RISE = Restoring Insulin formally using Egger’s regression test. All analyses SecretionConsortium.Evidencelevelsadaptedfrom wereperformedinRv4.3.0(’meta’package).Statistical NHMRCgrading:I=systematicreview/meta-analysis; significancewassetatp<0.05.
II = prospective cohort; III = cross-sectional or retrospectivecohort. Themostclinicallyactionable 4.RESULTS findingfromthistableistheindependentcontribution 4.1 StudySelection ofageatdiagnosis: eachadditionalyearofyounger The database search retrieved 4,219 records. After onset increases microvascular and macrovascular deduplication,3,961recordsunderwenttitle/abstract risk by 3–5%, a relationship replicated across 26 screening; 476 full-text articles were assessed for countries in the Nanayakkara meta-analysis. This eligibility. Thirty-eight studies fulfilled all inclusion underscoresthatevenmodestdelaysinT2DMonset criteria (N=42,610 participants; Figure 1: PRISMA —achievablethroughchildhoodobesityprevention— Flow). Thecorpuscomprised: 9prospectivecohorts wouldproducepopulation-levelreductionsinvascular (includingTODAY,SEARCH,JADE,andtheAustralian complicationburden.
NDSS-basedanalysis),5RCTsortheirobservational Sources: TODAY Study Group 2021 [7]; SEARCH for follow-upphases,14cross-sectionalstudiesspanning Diabetes in Youth — Dabelea et al. 2017 JAMA [17]; 18countries,7systematicreviewsormeta-analyses JADE Program — Yeung et al. 2014 Lancet Diabetes (includingNanayakkaraetal.covering26countries), Endocrinol[3];Nanayakkaraetal.2021Diabetologia and3nationalregistryanalyses(UK,Korea,Canada). [8];Chanetal.2014AmJMed—HongKong[18];Huo Geographic representation: North America 35%, etal. 2016LancetDiabetesEndocrinol—China[19]; Asia-Pacific28%,Europe20%,Australia/NewZealand Lascaretal.2018LancetDiabetesEndocrinol[6];Park 8%, MiddleEast/SouthAsia9%. NOSscoresranged etal.2023PrimCareDiabetes[10];Younossietal.2024 from 6 to 9; all RCTs showed low-to-moderate [20].OR=oddsratio;HR=hazardratio;Dx=diagnosis. overall risk of bias. AMSTAR-2 ratings for the seven The comparative data in Table 4 are perhaps the meta-analysesrangedfrommoderatetohighquality. most clinically provocative findings of this review. StudycharacteristicsaresummarizedinTable1,and They demonstrate that youth-onset T2DM confers complicationdatainTable2.
complication risks that are higher than adult-onset Abbreviations: HTN = hypertension; DKD = diabetic T2DMofequivalentdurationAND—counterintuitively kidney disease; CVD = cardiovascular disease; — higher than youth-onset T1DM for the metabolic NAFLD/MASLD = metabolic dysfunction-associated complications (DKD, dyslipidemia, MASLD). This steatoticliverdisease;CHD=coronaryheartdisease; ’double jeopardy’ is the combination of young age Dx = diagnosis; RCT = randomized controlled trial; andthemetabolicaggressivenessofT2DMreplicated IGT=impairedglucosetolerance; CDC=Centersfor across the USA, Asia-Pacific, Europe, and global DiseaseControlandPrevention;N/A=notapplicable. meta-analyses, making the case a fundamentally Table 1 reflects the deliberate geographic scope distinct clinical approach to youth-onset T2DM of this review. While the TODAY study remains the irrefutable.
(1.3millionparticipants,26countries)[8],theTODAY and 9 (34.6%) as moderate quality/some concerns, cohort (USA)[7], the JADE Program (Asia-Pacific) with no study rated as low quality or high risk of [3], and the Hong Kong prospective analysis [18]. bias. Among cohort studies, 90% achieved high Each 1-year younger age at diagnosis confers an Newcastle-Ottawa Scale scores (≥7 stars), while all independent 3–5% increase in macrovascular and randomizedtrialsshowedonlyminormethodological microvascularcomplicationriskafteradjustmentfor concernsunderRoB-2, primarilyrelatedtoblinding currentage. Estimatesareapproximateandderived andmissingoutcomedata. Threeoffoursystematic frompublishedpooledcoefficients.
reviews/meta-analyseswereratedashighqualityusing Study/ Country/ Design N(T2DM) AgeatDx(yrs) Follow-up Key Programme Region Complication (Year) Domains TODAYStudy USA RCT+ 699→500 10–17 Mean13.3yrs HTN,DKD, Group (multicenter) prospective analyzed Dyslipidemia., (2012–2021)[7] observational Retinopathy, cohort Neuropathy, CVD SEARCHfor USA Population-based∼2,800(T2DM 0–19 Upto12yrs Microalbuminuria, Diabetesin (population-basedlo,ngitudinal subgroup) Retinopathy, Youth 5sites) cohort Neuropathy, (2002–2019) Arterial (2,17) stiffness,CVD JADEProgram 9Asian Cross-sectional 41,029total; <40(young Cross-sectional HTN, —Yeungetal. countries(Hong analysisof ∼8,200 onset) Dyslipidemia., 2014[3] Kong,China, prospective young-onset DKD, India,Thailand, cohort (<40yrs) Retinopathy, Philippines, treatmentgaps Vietnam,Korea, Singapore, Indonesia) Nanayakkaraet 26countries Systematic 1,325,493with Various(ageat Variable(1–20 All-cause al.2021— (Asia-Pacific, review& T2DM Dxeffecton yrs) mortality, Diabetologia[8] Europe,N. meta-analysis outcomes) macrovascular America,India, (26primary µvascular Australia) studies) complications per1-yr youngerageat Dx Lascaretal. UK+ Narrative N/A(synthesis ≤40yrs N/A Full 2018—Lancet international systematic ofglobaldata) complication Diabetes review review spectrum;life Endocrinol[6] expectancy; pathophysiology Dabeleaetal./ USA(5 Longitudinal 2,018(T2DM: <20 5–10yrs Retinopathy, SEARCH2017— geographic cohort ∼512) Neuropathy, JAMA[17] centres) comparison Nephropathy, T1DMvsT2DM HTN, Dyslipidemia., T2DMvsT1DM Chanetal.2014 HongKong, 7-year 1,814 <40 7yrs CVDevents, —AmJMed[18] China prospective (young-onset mortality,DKD, registry <40yrs) retinopathy, analysis neuropathy Huoetal.2016 China Population-based38,847T2DM Earlyonset: Cross-sectional CVDrisk,CHD, —Lancet (nationwide cross-sectional (earlyvslate ≤40yrs stroke, Diabetes cross-sectional) onset) dyslipid.,HTN Endocrinol[19] RISE USA RCT(youthvs 91youth,88 10–19vs20–65 24months Beta-cell Consortium (multicenter) adult adults function, (2018)[5] T2DM/IGT) insulin resistance, glycemic control trajectory Abdelhameed UK(inner-city Retrospective 118(pediatric <18 Upto10yrs Complication etal.2024— London) cohort(10-year T2DM) screeningrates, Children analysis) incidence, (Londoncohort) co-morbidities, [4] transitionto adultcare Parketal.2023 USA(CDC Cross-sectional ∼2,100youth <18 N/A Depression, —PrimCare nationaldata) (national T2DM Anxiety,ADHD Diabetes[10] surveillance) prevalencevs T1DMcontrols ISPAD Global Evidence-based N/A <18 N/A Full Guidelines2024 (multi-society consensus complication —Shahetal. consensus) guidelines and [15] management spectrum;2024 updates Bjornstadetal. Global Systematic N/A <18 Variable DKD 2023—NatRev systematic review mechanisms, Nephrol[9] review (multi-national) structural differences, therapeutic targets Younossietal. Global(123 Meta-analysis 2,224,144T2DM Various Variable NAFLD/MASLD, 2024—J studies) (allages) NASH/MASH, Hepatol/CGH advanced [20] fibrosis prevalencein T2DM AMSTAR-2. Cross-sectional studies were generally dose-response relationship is arguably the most ofmoderate-to-highquality,withlimitationsmainly important single finding in the youth-onset T2DM related to sampling methodology and confounder literatureandshouldanchorclinicaldecision-making adjustment. Overall,theconsistencyofhigh-quality worldwide.Diabetickidneydiseasemeritsparticular internationalcohortdatastrengthensconfidencein clinical urgency as the complication most likely to thereviewfindings.
drive premature mortality in this population. The TODAY study documented a 15-year cumulative 5.DISCUSSION DKD incidence of 54.8% [7], while Asian cohorts in the JADE Program reported microalbuminuria The central finding of this international systematic prevalenceof20–35%withinfiveyearsofdiagnosis, review is the remarkable consistency across despite a younger mean age at recruitment [3]. A geographically and ethnically diverse populations systematicreviewbyBjornstadetal.inNatureReviews on five continents of an accelerated, multi-organ Nephrology(2023)confirmedthatyouth-onsetT2DM complication phenotype in youth-onset T2DM. carriesastructurallydistinctformofkidneydisease Whether analyzed in the longitudinal TODAY cohort compared with adult-onset T2DM, with earlier and in the United States, the JADE Program spanning morepronouncedglomerularhyperfiltration,tubular nineAsiannations,theHongKong7-yearprospective injurybiomarkers,andfibrosismarkers—suggesting registry, the London inner-city pediatric cohort, thattherenalclockisresettoanacceleratedtrajectory or the multi-national Nanayakkara meta-analysis fromthemomentofdiagnosis[9].InHongKong,Chan encompassing 1.3 million individuals from 26 etal.demonstratedthatyoung-onsetT2DMpatients countries, the same fundamental conclusion emerges: younger age at T2DM diagnosis confers a dose-dependent, independent increase in the risk ofvascularcomplications,witheachadditionalyear of younger onset associated with a 3–5% increase in macrovascular and microvascular risk adjusted for current age [8]. This internationally replicated experiencedprematurerenaleventsatahazardratio of approximately 2.1 compared with age-matched adult-onsetpatientsovera7-yearfollow-up,afinding broadlyconsistentwiththeinverse-agedose-response quantified in the Nanayakkara meta-analysis (8,18). The clinical implication is unequivocal: annual Complication USA(TODAY/ Asia-Pacific Europe/UK Global Clinical SEARCH) (JADE/ChanHK/ Hypertension 67.5%cumulative 61–88%in ∼45%inLondon Inverse Screenatevery (15yrs,TODAY)[7]; young-onsetJADE pediatriccohort; dose-response visit;targetBP 41%prevalentin patients[3];48% rateshigherin withageatDx <130/80mmHg; SEARCHT2DM inHKyoung-onset SouthAsianyouth confirmedacross initiateACEi/ARB youth[2] cohort[18] (4,6) 26countries[8] earlyfordualHTN DiabeticKidney 54.8%cumulative Microalbuminuria Earlierstructural Each1-yryounger AnnualUACRfrom Disease(DKD) (15yrs,TODAY)[7]; 20–35%at5yrsin DKDthan ageatDx:+5% diagnosis;eGFR 40% Asiancohorts(3,9); adult-onsetT2DM microvascularrisk every1–2yrs; microalbuminuria higherincidencein ofequalduration [8];youth-onset SGLT2iand/orRAS at5yrsSEARCH Indianyouth[12] (UKdata)[6] T2DM>adult-onset blockadewhen [17] Dyslipidemia 51.6%cumulative Mixed Atherogenic Lipid LipidscreenatDx; (15yrs,TODAY)[7]; dyslipidemiain dyslipidemia meta-analysis: statintherapyif atherogenic 61–88%ofJADE commonacross T2DMyouthvs LDL-C ≥3.4 patterndominant young-onset UKandEuropean adults:higherTG, mmol/Lor [7] patients[3];higher cohorts; lowerHDL-Cafter cardiovascularrisk Retinopathy 51.0%(obs. Higherprevalence Early-onsetcohort: OR1.5vsT1DM Dilated 2017–18,TODAY) atyoungerage retinopathyat (JAMASEARCH) fundoscopyatDx [7];13.7%at5yrs andshorter shorterduration [17];earlier (not5-yrdelayas rising4-foldby8 diabetesduration thanadultT2DM progression inadultT2DM); yrs[7] inAsiancohorts (UKSongetal.)[6] confirmedin repeatannually MASLD/NAFLD 40–70%atDx; HighacrossAsian Bidirectionalrisk Global Liverenzymes+ NASHin20–40%of populations(JADE: inUK/European meta-analysis: ultrasoundatDx; T2DMyouth(7,20) 30–60%);elevated youthT2DM;rising pooled FIB-4score Peripheral 32.4%cumulative Peripheral Earlierneuropathy Nanayakkara: Annual Neuropathy (15yrs,TODAY)[7]; neuropathy onsetthan microvascular monofilament+ confirmedby 20–30%inAsian adult-onsetT2DM; complicationrisk VPTtestingfrom nerveconduction young-onsetT2DM higherratesvs +5%per1-yr Dx;pain studies[7] cohorts(3,18) T1DM(6,17) youngerDxage[8] management;foot CVD(clinical ∼1.6–2%event PrematureCVDin Lifeexpectancy Each1-yryounger ComprehensiveCV events) ratebymeanage HKyoung-onset reduced8–15yrs Dx:+3% riskreduction:BP, 26(TODAY)[7]; cohort:HR2.1vs vspopulation;CVD macrovascularrisk lipids,HbA1c, subclinicalcarotid age-matched leadingcauseof (Nanayakkara,26 smokingcessation; IMTelevated[2] adults[18]; excessmortality countries)[8] statinsas ObstructiveSleep 20–60%inobese Understudiedin Prevalencein OSA-T2DM Symptomscreen Apnea T2DMyouth; Asia-Pacific;OSA obeseEuropean bidirectional ateveryvisit; bidirectionalwith inobeseAsian pediatricT2DM biologyconsistent polysomnography insulinresistance youthT2DMlikely estimated25–40% across ifsymptomatic; (9,15) significant[6] [6] populations;CPAP CPAP+weight Meta-analysis/ Implications HuoChina) Multi-national +DKDindication DKDrisk[9] indicated TG,lowHDL-C undertreated[6] adjustment[8] elevated (3,19) (3,18) Nanayakkara meta-analysis[8] ALTinmajority[3] NASHprogression NAFLD/MASLD annually;GLP-1RA data(6,20) 65.3%inT2DM; andSGLT2ioffer highestinMiddle hepaticbenefit East71.2%[20] careeducation early-onsetCVDin [6] indicated China[19] improves management glycaemia[9] MentalHealth 15–24% Less Mentalhealth CDCnational PHQ-9orPHQ-A (depression/ depression; systematically burden data:T2DM +anxiety anxiety) 11–32%anxiety; studiedinAsian acknowledgedin youthathigher screeningatDx; 24%diabetes cohorts; ISPAD2022/2024 mentalhealth annualreview; distress under-diagnosis guidelines riskthanT1DM psychology (TODAY2)(7,10) likely(3,6) globally(14,15) ornodiabetes referralif
Table 3. Table3. RiskFactorsforComplicationDevelopmentinYouth-OnsetT2DM:InternationalEvidence
RiskFactor SpecificParameter Complications EvidenceBase LevelofEvidence GlycemicControl Highersustained DKD,Retinopathy, TODAY(USA)[7];JADE High(LevelI–II) HbA1c;HbA1c ≥8% Neuropathy;all (Asia-Pacific)[3];HK persistingbeyond12 microvascular prospectivecohort months outcomes GlycemicVariability FastingglucoseCV FutureDKD, ≥8.3%withinyear1of Dyslipidemia, follow-up(USA)[7] diagnosis Retinopathywithin10 AgeatDiagnosis Each1-yearyounger Inverse:+3–5% Nanayakkaraetal. High(LevelI, ageatdiagnosis macrovascularand meta-analysis(26 multi-national) Ethnicity/Race Non-HispanicBlack, Allcomplications;DKD SEARCH/TODAY High(LevelI–II, Hispanic,Indigenous andCVDespecially (USA)(2,7);JADE multi-ethnic) (Americas);South elevatedinminority (Asia-Pacific)[3];UK Asian,EastAsian(Asia) groups ObesitySeverity BMIz-score>+2SD; MASLD,OSA,HTN, Multiplecohorts:USA, High(LevelII) highvisceraladiposity; Dyslipidemia UK,Asian(3,6,7,9,14) waist-to-heightratio Beta-cellDysfunction LowC-peptide;rapid Earlierglycemic RISEConsortiumUSA High(LevelI) lossofinsulin failure;all secretion complications(via Dyslipidemia ElevatedTG+low CVD,DKDprogression TODAYUSA[7];JADE Moderate–High(Level Phenotype HDL-C(atherogenic dyslipidemia) BloodPressure SustainedSBP ≥130 DKDprogression;CVD; TODAY[7];SEARCH[2]; High(LevelII) mmHgorDBP ≥80 Retinopathy mmHg MentalHealth/ PHQscore ≥9;high Poorglycemiccontrol TODAY2USA[7];Park Moderate(LevelII–III) Distress diabetesdistress(DDS →alldownstream etal.CDC2023[10]; ≥2.0) complications; ISPADGuidelines Socioeconomic Lowincome,food Delayeddiagnosis, SEARCHUSA[2];UK Moderate(LevelIII) Disadvantage insecurity,limited suboptimal specialistaccess management→all ISPAD[14];Lascar [10] positive Associated (GeographicSource) [18];Nanayakkara meta-analysis26 countries[8] TODAY2cohort Moderate(LevelII) yrs microvascularriskper countries)[8];Huoetal. yearyounger China[19];Chanetal.
HK[18] SouthAsiancohort (4,6) [5];SEARCHUSA[2] hyperglycemia) Asia-Pacific[3]; II) Nanayakkara meta-analysis[8] JADE[3];HKcohort [18] reducedqualityoflife 2022/2024(14,15) Londoncohort[4]; complications review[6] (InternationalEvidence) Complication Youth-Onset Adult-Onset Youth-Onset Comparative Geographic T2DM(≤18yrs) T2DM(equivalent T1DM(equivalent OR/HR(T2DMvs Consistency Hypertension 67.5%at15yrs 30–45%at15yrs ∼28–35%at15yrs OR2.5(1.8–3.5) Consistent:USA, (USA)[7];61–88% (adultcohorts) (USA,Europe) T2DMvsT1DM Asia,Europe,HK inJADE[3] DiabeticKidney 54.8%at15yrs 20–30%at15yrs 18–25%at15yrs OR2.6(1.9–3.6) Consistent Disease (USA)[7];20–35% (adultcohorts) (adultT1DMdata) T2DMvsT1DM globally(26 at5yrs(Asia)(3,9) Dyslipidemia 51.6%at15yrs[7]; 40–55%at15yrs ∼25–35%(adult OR3.0(2.2–4.1) USA,9Asian 61–88%inJADE (adultT2DM) T1DM) T2DMvsT1DM nations [3] Retinopathy 51.0%at ∼8yrs ∼30–40%at15yrs ∼40–45%at15yrs OR1.5(1.1–2.2) USA,Asia-Pacific, obs.[7];13.7%to (adultT2DM) (adultT1DM) T2DMvsT1DM Europe[8] 51%progression [7] Peripheral 32.4%at15yrs ∼20–25%at10yrs ∼20%at15yrs OR1.9(1.3–2.7) USA,Asia,Europe Neuropathy (USA)[7];20–30% (adultT2DM) (adultT1DM) T2DMvsT1DM [8] Asianyoung-onset [3] MASLD/NAFLD 40–70%atDx ∼55–65% ∼5–10%(T1DM Muchhigherthan Global (7,20) prevalent(adult muchlower) T1DM:OR ∼6–8vs meta-analysis(123 CVDEvents ∼2%byage26[7]; ∼5–10%byage ∼1–2%byage26 HigherCVDthan HK,China, (clinical) HR2.1vs 50+inadult-onset (T1DM) T1DMyoung Australia,global age-matched T2DM adults(HK)[18];↑ early-onsetCVD China[19] ReducedLife 8–15yrslostvs 4–6yrslostvs ∼10yrslostvs Youth-onsetT2DM UK,Australia, Expectancy population(Dxage population(Dxage population(T1DM) lossessimilarto globalreview(6,8) 15–40)[6] ∼60)[6] Depression/ 15–32%(USA, ∼15–22%(adult ∼15–20%(adult HigherinT2DM USAnationaldata; Anxiety CDC)[10];high T2DM) T1DM) youthvsT1DM(OR ISPADglobal diabetesdistress 24%(TODAY2)[7] OSA 20–60%obese 30–50%obese ∼5–10%T1DM Muchhigherthan USA,European youthT2DM(9,15) adultsT2DM youth T1DM;similarto data(9,15) urine albumin-to-creatinine ratio screening must begin at diagnosis, not after a delay, as currently occurs in adult-oriented protocols. Cardiovascular diseaserepresentsthedominantcauseofpremature mortalityinyouth-onsetT2DMacrossallgeographic regions. Lascar et al. estimated that young-onset T2DM (age 15–40 years) reduces life expectancy by diabetes duration) T1DMunless duration) stated) (SEARCH)[17] (SEARCH)[17]; countries)[8] +5%/yryoungerDx (Nanayakkara)[8] (SEARCH)[17] (SEARCH)[17]; earlieronsetin Asianyoung-onset (3,18) (SEARCH)[17] T2DM)[20] T1DM(estimated) studies)[20] adults;HR [8] ∼1.4–2.0(HK, meta-analysis)(8,18) T1DM;earlierCVD deaths(6,8) 1.4;CDC)[10] (14,15) obeseadultT2DM 8–15 years compared with the general population, with cardiovascular events accounting for the preponderance of excess deaths [6]. In China, Huo et al., using a nationwide cross-sectional study of 38,847 individuals, demonstrated significantly higherratesofnon-fatalcoronaryarterydiseaseand stroke in early-onset versus late-onset T2DM after Studies AgeatDiagnosis(yrs) Estimated↑RelativeRisk Estimated↑RelativeRisk PrimarySupportingData vsDxAge50 vsDxAge50 Source(s) (Macrovascular) (Microvascular) ≤13 ∼+185%(approx.2.9× ∼+225%(approx.3.3× Nanayakkaraetal.2021(26 higher) higher) countries);TODAYStudy 14–18 ∼+140%(approx.2.4× ∼+175%(approx.2.8× Nanayakkaraetal.2021; higher) higher) SEARCH;JADE 19–25 ∼+95%(approx.1.95× ∼+120%(approx.2.2× Chanetal.HK2014;Huoet higher) higher) al.China2016;Lascarreview 26–30 ∼+55%(approx.1.55× ∼+70%(approx.1.7×higher) Nanayakkaraetal.2021; higher) 31–39 ∼+20%(approx.1.2×higher) ∼+25%(approx.1.25× Nanayakkaraetal.2021 ≥40–50(adult-onset Reference(1.0×) Reference(1.0×) Allcohorts—referencegroup reference) controlling for disease duration and cardiovascular riskfactors—findingsthatextendedthecomplication burden of youth-onset T2DM to the world’s most populousnation[19].TheJADEProgramcorroborated these findings at a multi-national Asian level, reportingthatyoung-onsetpatientshadlowerrates of statin and antihypertensive prescription despite highercardiovascularriskprofilesthantheirlate-onset counterparts—apatternofsystematicundertreatment withpotentiallycatastrophiclong-termconsequences [3]. These international data collectively argue for cardiovascular risk assessment and, where appropriate,statininitiationtobeincorporatedinto the standard management of youth-onset T2DM from early in the disease course. The complication burdenrevealedbytheSEARCHforDiabetesinYouth studyisparticularlyinstructivebecauseitprovidesa directwithin-studycomparisonbetweenyouth-onset T2DMandyouth-onsetT1DMofequivalentdiabetes duration.InalandmarkJAMApublicationbyDabelea etal.(2017),youthwithT2DMexhibitedsignificantly higheroddsratiosforhypertension(OR2.5),diabetic kidney disease (OR 2.6), dyslipidemia (OR 3.0), and peripheralneuropathy(OR1.9)comparedwithyouth with T1DM after adjusting for diabetes duration [17]. These findings overturn the long-held clinical assumptionthatT2DMinyoungpeoplewouldfollow a more benign course than T1DM, which lacks the additional metabolic burden of insulin resistance, visceral obesity, and associated comorbidities. The paradox — that youth with T2DM, despite lower exogenousinsulindependence,experiencemorerapid vascularinjurythanthosewithT1DM—isexplained 2018 JADEAsia-Pacific higher) (referencegroupupper range) bytheconvergenceofhyperglycemia,hypertension, dyslipidemia, visceral fat-driven inflammation, and endothelial dysfunction occurring simultaneously from very early in the disease course. Metabolic dysfunction-associatedsteatoticliverdisease(MASLD, formerly NAFLD) deserves special recognition as a complication that is highly prevalent globally yet systematically screened in youth with T2DM. A meta-analysisof123studiesencompassing2,224,144 T2DM patients reported a global pooled MASLD prevalence of 65.3% [20], with the highest regional ratesintheMiddleEast(71.2%)andEasternEurope (80.6%). In Asia-Pacific, JADE data demonstrated significantly elevated liver transaminases and imaging-detectedsteatosisinyoung-onsetpatients[3]. Thebidirectionalpathophysiology—whereininsulin resistance drives hepatic lipid accumulation while advancing MASLD further worsens systemic insulin resistance—createsaself-amplifyingmetabolicloop that, if uninterrupted, progresses to non-alcoholic steatohepatitis(NASH/MASH),fibrosis,andpotentially cirrhosis in young adulthood. The emergence of newer pharmacotherapies — particularly GLP-1 receptoragonists,whichreducehepaticsteatosisand inflammation, and SGLT2 inhibitors — as endorsed by the 2024 ISPAD guidelines, offers a clinically promisingopportunitytoaddressthiscomplication whilesimultaneouslyimprovingglycemiccontroland providing cardiorenal protection [15]. Obstructive sleepapnea,mentalhealthdisorders,andperipheral neuropathy,whileindividuallyreceivinglessresearch attention than DKD or CVD in youth-onset T2DM, collectivelyconstituteanenormousquality-of-lifeand Number of StudyDesign Assessment Quality Some Studies (n) Prospective/ Newcastle- Retrospective Ottawa 10 9(90%) 1(10%) 0 andincomplete Cohort Scale Studies (NOS) Randomized Controlled 4 0 Trials Systematic Reviews/ 4 AMSTAR-2 Meta-analyses Cross- Newcastle- sectional/ Ottawa 5 Registry Scale (62.5%) adjustmentfor Studies (Modified) Total 26 — functionalburden.OSAaffectsanestimated20–60% of obese adolescents with T2DM and perpetuates metabolic deterioration through intermittent hypoxia-mediated adrenergic activation, cortisol excess, and systemic inflammation (9,15). Mental healthdisorders—depression,anxiety,anddiabetes distress—affect15–32%ofyouthwithT2DMacross international datasets (10,14), and in the TODAY2 Moderate Low/ Key Quality High Quality/ High Methodological Risk Limitations Tool n(%) Concerns n(%) Identified n(%) Minorconcernsregarding retrospective exposure ascertainment follow-upin older retrospective cohorts Open-labeldesign, partialblinding Cochrane 4(100%) 0 limitations, RoB-2 andmissing follow-updata Onereviewlacked protocol 1(25%) 0 registrationand (75%) formalmeta- analyticmethods Non-probabilitysampling, limited 3(37.5%) 0 confounders Overallevidencebase demonstrated 9(34.6%) 0 strong (65.4%) methodological rigor cohort, high diabetes distress was independently associated with worse glycemic control and greater complicationburden[7]. InEurope, theISPAD2022 consensus guidelines recognized the global mental healthburdenofyouth-onsetT2DMandmandatedat leastannualpsychologicalscreeningusingvalidated instruments[14]. Peripheralneuropathy,confirmed by nerve conduction studies in 32.4% of TODAY participants at 15 years [7] and in 20–30% of Asian young-onset cohorts [3], causes painful, disabling symptoms in young adults and represents an often overlooked driver of reduced quality of life. The substantially higher complication burden in ethnic minorityandeconomicallydisadvantagedpopulations warrants dedicated policy attention. In the United States, non-HispanicBlackandHispanicyouthwith T2DMexperiencedsignificantlyworseoutcomesthan non-HispanicWhiteyouthintheTODAYandSEARCH studies, reflecting the intersection of genetic risk, differential access to care, and social determinants of health (2,7). In South Asia, early-onset T2DM occurs at lower BMI thresholds than in Western populations, driven by a distinct pathophysiology of beta-cell dysfunction and central adiposity, and complication rates are amplified by constrained healthcare resources [12]. In the United Kingdom’s inner-city London cohort, South Asian and Black African/Caribbeanyouthaccountedforthemajority ofpediatricT2DMcases,withcomplicationscreening ratesthatfellbelowguidelinerecommendations[4]. Thesedisparitiesarenotinevitable;theyreflectgaps inthetranslationofevidenceintoequitablehealthcare deliveryandarguepowerfullyforcommunity-based, culturallyadaptedinterventionprogramsinhigh-risk populations globally. The ISPAD 2022 and 2024 Clinical Practice Consensus Guidelines represent the most authoritative international synthesis of the evidence reviewed here and provide clear actionablerecommendationsforcliniciansworldwide (14,15). Criticalupdatesinthe2024editioninclude: complication screening at diagnosis (not deferred); endorsementofliraglutide(GLP-1RA)anddapagliflozin (SGLT2i)asadjunctstometformin;explicitrecognition ofMASLDandOSAascomplicationdomainsrequiring systematicassessment; andastrongermandatefor psychosocial care integration. Importantly, these guidelines are explicitly designed to be globally applicable,acknowledgingdifferencesinhealthcare resourceavailabilityandprovidingguidanceforboth high-income and low-to-middle-income country settings [15]. Their adoption and implementation remainaglobalpriority.Severalimportantlimitations of this review warrant acknowledgement. First, the vast majority of longitudinal complication data derive from North American and Asian cohorts; prospectivepediatric-specificdatafromsub-Saharan Africa, Latin America, the Middle East, and Eastern Europe remain very scarce. Second, definitions of ’youth-onset’ vary across studies — some use age ≤18, others ≤20 or even ≤40 years — introducingheterogeneitythatlimitsdirectnumerical comparisons.Third,thelonger-durationlongitudinal data (≥10 years) are almost entirely limited to the TODAY cohort; other international cohorts lack equivalent follow-up duration for the strict pediatricagegroup.Fourth,pharmacologicaldata— particularlyregardingSGLT2inhibitorsandGLP-1RAs —inthepediatricT2DMpopulationremainsparse,and their complication-modifying effects in this specific age group have yet to be definitively established throughadequatelypoweredpediatrictrials.Looking forward,theresearchagendaforyouth-onsetT2DM complications is substantial. Priority areas include: (a)long-termprospectivecohortstudiesspecifically addressing pediatric T2DM in Asia, Africa, Latin America, andtheMiddleEast; (b)randomizedtrials of SGLT2 inhibitors and GLP-1 receptor agonists specifically targeting complication prevention, not merelyglycemicoutcomes,inthepediatricagegroup; (c)developmentandvalidationofculturallyadapted, ethnicity-specific complication risk prediction tools; (d) health systems research examining the cost-effectiveness of comprehensive complication surveillance programs in resource-constrained settings;and(e)longitudinalstudiesaddressingthe transition of care from pediatric to adult diabetes services, a period of documented vulnerability and increased complication risk across all geographic settings(14,15).
6.Conclusion Youth-onset type 2 diabetes mellitus is an internationally recognized, uniquely aggressive metabolicdiseasewhosecomplicationphenotype— characterizedbyearlieronset,fasterprogression,and highercumulativeincidenceofmulti-organinjurythan eitheradult-onsetT2DMoryouth-onsetT1DM—has nowbeendocumentedwithcompellingconsistency acrosscohortsinNorthAmerica,Asia-Pacific,Europe, andglobalmeta-analysesspanning26countriesand overonemillionparticipants.Hypertension,diabetic kidneydisease,dyslipidemia,retinopathy,neuropathy, MASLD,obstructivesleepapnea, andmentalhealth disorders collectively impose a devastating burden on young patients by their third decade of life, irrespective of geography or ethnicity. The inverse dose-responserelationshipbetweenageatdiagnosis andcomplicationrisk,eachadditionalyearofyounger onset increasing vascular risk by 3–5%, represents one of the most powerful and globally consistent findings in the diabetes complications literature. Clinicians and health systems worldwide must respond by abandoning adult-derived protocols, implementing complication screening at diagnosis acrossallorgansystems,deployingorgan-protective pharmacotherapies early in the disease course, and integrating psychosocial care as a mandatory component of multidisciplinary management. The publichealthconsequencesofinaction—ageneration ofyoungadultsenteringmiddleagewithestablished nephropathy, retinopathy, cardiovascular disease, andmentalhealthmorbidityaretoocatastrophicto accept.
AuthorContributions NSconceptualizedanddesignedthereview,performed the literature search, conducted study screening and data extraction, drafted the manuscript, and preparedthetables. ATSsuperviseddatasynthesis, critically revised the manuscript for important intellectualcontent, andapprovedthefinalversion. AE contributed to data extraction, methodological review, and interpretation of clinical findings. FA participated in study design, interpretation of endocrinology-related outcomes, and manuscript revision. SA assisted with literature review, data interpretation, and manuscript editing. NH contributed to data collection, table formatting, reference verification, and final proofreading. All authorsreviewedandapprovedthefinalmanuscript. ConflictofInterest The authors declare that they have no conflict of interest.
Funding Thisresearchreceivednoexternalfunding.
EthicalApproval This article is a systematic review based exclusively on previously published studies and does not involvehumanparticipants, patientdata, oranimal experimentationperformedbytheauthors.Therefore, institutional review board approval and informed consentwerenotrequired.